The proposed 2-week, double-blind, crossover, proof of concept study aims to measure and
manipulate core neurochemical (i.e., dysregulated brain GABA/glutamate homeostasis) and
neurobehavioral (i.e., elevated impulsivity) dysfunctions characteristic of individuals with
cannabis use disorder (CUD) and Bipolar Disorder (BD), using a medication that has been shown
to increase cortical GABA (i.e., gabapentin) levels in past research, and to evaluate
medication-related changes in response inhibition (go no-go) and cannabis cue reactivity
functional Magnetic Resonance Imaging tasks, as well as cannabis use, mood symptoms
(including anxiety and sleep), and impulsivity in individuals with CUD+BD.